A newly published review article highlights the emerging importance of the immunoproteasome in the development and progression of diabetes and its wide-ranging complications, offering fresh perspectives on future therapeutic strategies. The findings position this specialized protein complex as a critical regulator of inflammation, metabolism, and cellular health.
The immunoproteasome, a modified form of the proteasome responsible for protein degradation, plays a central role in maintaining cellular balance and immune responses. Increasing evidence shows that it directly influences pancreatic β-cell function, glucose metabolism, and lipid regulation, all of which are essential processes disrupted in diabetes.
In type 1 diabetes, the immunoproteasome contributes to immune-driven damage of insulin-producing cells by shaping antigen presentation and activating immune pathways. In type 2 diabetes, it exhibits a more complex role, simultaneously promoting chronic inflammation while also helping protect cells from stress-induced damage. This dual function underscores its importance as both a driver of disease and a potential protective mechanism.
The review also emphasizes the immunoproteasome’s involvement in major diabetes-related complications, including cardiovascular disease, kidney damage, and retinal disorders. Elevated activity of specific subunits has been linked to increased fibrosis, oxidative stress, and inflammatory signaling, all of which contribute to organ dysfunction. At the same time, targeted modulation of these pathways shows potential to improve outcomes by restoring metabolic balance and reducing tissue damage.
Particular attention is given to the immunoproteasome’s influence on glycolipid metabolism, where it affects energy regulation and insulin sensitivity. Modulating its activity has been associated with improved metabolic efficiency, reduced fat accumulation, and better glucose handling, pointing toward new avenues for intervention.
The article further identifies several promising therapeutic approaches, including selective inhibitors that target key immunoproteasome subunits. These compounds demonstrate the ability to reduce inflammation, limit fibrosis, and improve metabolic health, suggesting a new class of treatments for managing both diabetes and its complications.
Overall, the review underscores the immunoproteasome as a multifaceted regulator in diabetes, bridging immune responses and metabolic processes. By deepening understanding of its mechanisms, this work opens the door to innovative strategies aimed at improving patient outcomes and addressing the growing global burden of diabetes.
.
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 8.4 |Impact Factor: 9.4
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)
# # # # # #
Reference
Mengwen Wang, Lingyun Luo, Lei Dai, Hesong Zeng, Hongjie Wang, The role of immunoproteasome in diabetes and diabetes-related complications, Genes & Diseases, Volume 13, Issue 3, 2026, 101861, https://doi.org/10.1016/j.gendis.2025.101861

Funding
National Natural Science Foundation of China 82270368
Hubei Provincial Natural Science Foundation of China 2024AFB062
Cultivation Fund by Tongji Hospital affiliated to Tongji Medical College HUST (Hubei, China) 2023B04